Contemporary embolization strategies for active sac management during EVAR.
Reports Q4 revenue $60.6M, consensus $51.9M. “We continue to make excellent progress with our clinical and preclinical molecular glue degrader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results